Expand PLI scheme for pharma to make it research-linked, says industry

So far 55 drug manufacturers have been selected under the PLI scheme for pharma.

Indian pharma industry captains feel that the current production linked incentive (PLI) scheme for the pharmaceutical industry can be expanded to link it to research, and more specifically for research in biologics and biosimilars.

Speaking at BioAsia 2022, Kiran Mazumdar Shaw, executive chairperson, Biocon Group, said that there needs to be a different PLI scheme that needs to focus on the emerging opportunities for Indian pharma. “As a nation we need to start moving towards large molecules of biologics. There is a huge growing interest in combination immuno-therapies. Can we leap-frog? The PLI scheme was far too skewed far too